AstraZeneca PLC (AZN)vsPolyPid (PYPD)
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
PYPD
PolyPid
$5.15
-0.19%
HEALTHCARE · Cap: $109.48M
Smart Verdict
WallStSmart Research — data-driven comparison
AZN leads profitability with a 17.0% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
PYPD
Avoid19
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Intrinsic value data unavailable for PYPD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Trading at 19.1x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : PYPD
The strongest argument for PYPD centers on Debt/Equity.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : PYPD
The primary concerns for PYPD are Price/Book, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
AZN profiles as a mature stock while PYPD is a value play — different risk/reward profiles.
PYPD carries more volatility with a beta of 1.42 — expect wider price swings.
AZN is growing revenue faster at 6.4% — sustainability is the question.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (60/100 vs 19/100), backed by strong 17.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
PolyPid
HEALTHCARE · BIOTECHNOLOGY · USA
PolyPid Ltd., an advanced stage biopharmaceutical company, develops, manufactures and markets products based on the Polymer Lipid Encapsulation Matrix (PLEX) platform to address unmet medical needs. The company is headquartered in Petah Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?